AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17037894 — intervention group
Group type: EXPERIMENTAL
Intervention: Foramatron D10
Number of subjects: 36
Study 17037894 — intervention group
Group type: COMPARATOR
Intervention: Apex NRG
Number of subjects: 36
Study 17037894 — intervention group
Group type: COMPARATOR
Intervention: Apit 7
Number of subjects: 36
Study 15213896 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum hepatocyte growth factor (HGF) in BA patients
Number of subjects: 28
Study 15213896 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum hepatocyte growth factor (HGF) in BA patients with poor outcome
Number of subjects: 28
Study 15213896 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum hepatocyte growth factor (HGF) in BA patients with fair outcome
Number of subjects: 28
Study 15213896 — intervention group
Group type: COMPARATOR
Intervention: Serum hepatocyte growth factor (HGF) in controls
Number of subjects: 28
Study 15213896 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum hepatocyte growth factor (HGF) in group A (good outcome)
Number of subjects: 28
Study 15213896 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum hepatocyte growth factor (HGF) in group B (fair outcome)
Number of subjects: 28
Study 15213896 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum hepatocyte growth factor (HGF) in group C (poor outcome)
Number of subjects: 28
Study 16677162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulcerative colitis patients (active disease)
Number of subjects: 30
Study 16677162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulcerative colitis patients (remission)
Number of subjects: 30
Study 16677162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulcerative colitis patients (≥4 recurrences)
Number of subjects: 30
Study 16677162 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 10230943 — intervention group
Group type: EXPERIMENTAL
Intervention: Early extubation (mean delay, 3.49±2.21 hours)
Number of subjects: 48
Study 10230943 — intervention group
Group type: COMPARATOR
Intervention: Late extubation (mean delay, 10.32±1.75 hours)
Number of subjects: 48
Study 10230943 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (early and late extubation)
Number of subjects: 48
Study 9091555 — intervention group
Group type: EXPERIMENTAL
Intervention: TUIP alone
Number of subjects: 74
Study 9091555 — intervention group
Group type: EXPERIMENTAL
Intervention: TUIP + LHRH analogue
Number of subjects: 74
Study 1914480 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective parenteral and enteral antisepsis regimen (oral nonabsorbable antimicrobial agents: polymyxin E, gentamicin, and amphotericin B; parenteral cefotaxime)
Number of subjects: 50
Study 1914480 — intervention group
Group type: COMPARATOR
Intervention: Perioperative antibiotic prophylaxis or antibiotic therapy according to clinical or microbiological evidence of infection
Number of subjects: 50
Study 7037661 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutonidin (2-4 mg daily)
Number of subjects: 0
Study 7037661 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (20-40 mg daily)
Number of subjects: 0
Study 31981227 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 76
Study 31981227 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 76
Study 30782917 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered dietary intervention with a mail-delivered workbook and scheduled phone calls from a dietitian over 4 months
Number of subjects: 140
Study 30782917 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 140
Study 28118856 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS-based neurofeedback training in VR
Number of subjects: 90
Study 28118856 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS-based neurofeedback training in 2D
Number of subjects: 90
Study 28118856 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyogram-based biofeedback training in VR
Number of subjects: 90
Study 27026145 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 370
Study 24903197 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemostatic sealant (FloSeal™)
Number of subjects: 100
Study 24903197 — intervention group
Group type: COMPARATOR
Intervention: Bipolar coagulation
Number of subjects: 100
Study 22894887 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercessory prayer
Number of subjects: 999
Study 19649577 — intervention group
Group type: COMPARATOR
Intervention: Conventional anchorage (transpalatal arch)
Number of subjects: 20
Study 19649577 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal anchorage via mini-implants in the anterior palate
Number of subjects: 20
Study 17301557 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC114/r 400/100 mg once daily
Number of subjects: 318
Study 17301557 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC114/r 800/100 mg once daily
Number of subjects: 318
Study 17301557 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC114/r 400/100 mg twice daily
Number of subjects: 318
Study 17301557 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC114/r 600/100 mg twice daily
Number of subjects: 318
Study 17301557 — intervention group
Group type: COMPARATOR
Intervention: CPI(s)
Number of subjects: 318
Study 17301557 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC114/r
Number of subjects: 318
Study 15135548 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (TD)
Number of subjects: 7
Study 15135548 — intervention group
Group type: COMPARATOR
Intervention: Control procedure (placebo)
Number of subjects: 7
Study 11588459 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation with six aliquots of 20-mL sterile normal saline at 37 degrees C infused through the bronchoscope.
Number of subjects: 27
Study 11588459 — intervention group
Group type: COMPARATOR
Intervention: Control groups (not specified in detail).
Number of subjects: 27
Study 9887897 — intervention group
Group type: EXPERIMENTAL
Intervention: Buteyko breathing techniques (BBT)
Number of subjects: 39
Study 9887897 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 7880228 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone (750 mg orally with meals three times daily for 21 days)
Number of subjects: 109
Study 7880228 — intervention group
Group type: COMPARATOR
Intervention: Pentamidine (3 to 4 mg per kg body weight intravenously once daily for 21 days)
Number of subjects: 109
Study 7880228 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone
Number of subjects: 109
Study 7880228 — intervention group
Group type: COMPARATOR
Intervention: Pentamidine
Number of subjects: 109
Study 7880228 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone and Pentamidine
Number of subjects: 109
Study 31834064 — intervention group
Group type: EXPERIMENTAL
Intervention: RTP group (received sports return‐to‐play guideline information)
Number of subjects: 828
Study 31834064 — intervention group
Group type: COMPARATOR
Intervention: No-RTP group (did not receive sports return‐to‐play guideline information)
Number of subjects: 828
Study 31834064 — intervention group
Group type: EXPERIMENTAL
Intervention: RTP group
Number of subjects: 828
Study 31834064 — intervention group
Group type: COMPARATOR
Intervention: No-RTP group
Number of subjects: 828
Study 30993344 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% fermented feed
Number of subjects: 720
Study 30993344 — intervention group
Group type: COMPARATOR
Intervention: 0.0% fermented feed (control)
Number of subjects: 720
Study 28335877 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 81
Study 28335877 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic Therapy (PDT)
Number of subjects: 81
Study 26508386 — intervention group
Group type: EXPERIMENTAL
Intervention: CoreValve TAVR
Number of subjects: 634
Study 23261707 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality exposure in multiple contexts
Number of subjects: 30
Study 23261707 — intervention group
Group type: COMPARATOR
Intervention: Virtual reality exposure in single context
Number of subjects: 30
Study 22117602 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-faceted quality improvement intervention (training of health workers, facilitation, supervision, face-to-face feedback)
Number of subjects: 1160
Study 22117602 — intervention group
Group type: COMPARATOR
Intervention: Partial intervention (didactic training and written feedback only)
Number of subjects: 1160
Study 22117602 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-faceted quality improvement intervention
Number of subjects: 1160
Study 18700212 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 3069
Study 18700212 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 3069
Study 18700212 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin reuptake inhibitors
Number of subjects: 3069
Study 18700212 — intervention group
Group type: EXPERIMENTAL
Intervention: Other antidepressants
Number of subjects: 3069
Study 18700212 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 3069
Study 17086007 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical devices for chronic disease management
Number of subjects: 0
Study 17086007 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical agents for chronic disease management
Number of subjects: 0
Study 17086007 — intervention group
Group type: EXPERIMENTAL
Intervention: COX-2 anti-inflammatory drugs
Number of subjects: 0
Study 17086007 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable devices requiring catheter-based surgical procedures
Number of subjects: 0
Study 14534587 — intervention group
Group type: EXPERIMENTAL
Intervention: Waking reactivation of previously consolidated memory
Number of subjects: 0
Study 14534587 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep stages
Number of subjects: 0
Study 14534587 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor skill finger-tapping task
Number of subjects: 0
Study 11061574 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg per day for 9 days)
Number of subjects: 8
Study 9352161 — intervention group
Group type: EXPERIMENTAL
Intervention: Dicea cellulose membrane
Number of subjects: 0
Study 9352161 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose diacetate membrane
Number of subjects: 0
Study 9352161 — intervention group
Group type: COMPARATOR
Intervention: Low flux polysulfone membrane
Number of subjects: 0
Study 9352161 — intervention group
Group type: EXPERIMENTAL
Intervention: All membranes
Number of subjects: 0
Study 8460612 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing 21.9 mumol Zn/d (I)
Number of subjects: 11
Study 8460612 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing 37.5 mumol Zn/d (II)
Number of subjects: 11
Study 8460612 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing 51.6 mumol Zn/d (III)
Number of subjects: 11
Study 8460612 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing 67.8 mumol Zn/d (IV)
Number of subjects: 11
Study 8460612 — intervention group
Group type: COMPARATOR
Intervention: Diet containing 159 mumol Zn/d (X)
Number of subjects: 11
Study 3709018 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol aerosol (180 mcg, 2 puffs) followed by hourly albuterol aerosol for 5 hours (10 puffs = 900 mcg)
Number of subjects: 15
Study 3709018 — intervention group
Group type: COMPARATOR
Intervention: Albuterol aerosol (180 mcg, 2 puffs) followed by hourly placebo for 5 hours
Number of subjects: 15
Study 29027324 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher circulating miR‐132 levels
Number of subjects: 953
Study 27633766 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol e‐cigarettes
Number of subjects: 88
Study 27633766 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate e‐cigarettes
Number of subjects: 88
Study 27633766 — intervention group
Group type: EXPERIMENTAL
Intervention: Cherry e‐cigarettes
Number of subjects: 88
Study 27633766 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco e‐cigarettes
Number of subjects: 88
Study 22738284 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 60
Study 22738284 — intervention group
Group type: COMPARATOR
Intervention: Flexibility Training (FT)
Number of subjects: 60
Study 23787163 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine screening for Coxiella burnetii infection with immediate analysis of serum samples for IgM and IgG (phase I/II) and treatment during pregnancy
Number of subjects: 1229
Study 23787163 — intervention group
Group type: COMPARATOR
Intervention: Control group with sera frozen for analysis after delivery
Number of subjects: 1229
Study 20442540 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin 20,000 KIU/kg after induction, 20,000 KIU/kg added to pump prime, 20,000 KIU/kg/hour infusion for three hours
Number of subjects: 24
Study 20442540 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin 30,000 KIU/kg after induction, 30,000 KIU/kg added to pump prime, 30,000 KIU/kg/hour infusion for three hours
Number of subjects: 24
Study 20442540 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin 40,000 KIU/kg after induction, 40,000 KIU/kg added to pump prime, 40,000 KIU/kg/hour infusion for three hours
Number of subjects: 24
Study 20442540 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin 40,000 KIU/kg
Number of subjects: 24
Study 18468815 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (150 mg twice daily)
Number of subjects: 73
Study 18468815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 15753526 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 20
Study 15753526 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 20
Study 12600228 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 or 600mg once daily
Number of subjects: 147
Study 10580785 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist action level 1 (waist circumference >=94 cm in men and >=80 cm in women)
Number of subjects: 32978
Study 10580785 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist action level 2 (waist circumference >=102 cm in men and >=88 cm in women, BMI >=30 kg/m2)
Number of subjects: 32978
Study 10580785 — intervention group
Group type: COMPARATOR
Intervention: Cut-off points based on BMI (>=25 kg/m2) and waist-to-hip ratio (>=0.95 for men, >=0.80 for women)
Number of subjects: 32978
Study 8732716 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (60% energy from carbohydrate, 20% from fat)
Number of subjects: 18
Study 8732716 — intervention group
Group type: COMPARATOR
Intervention: Low-carbohydrate diet (40% energy from carbohydrate, 40% from fat)
Number of subjects: 18
Study 1718369 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium-rich diet
Number of subjects: 400
Study 1718369 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (Control)
Number of subjects: 400
Study 7063178 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cm3 of Xylocitin 2% with 0.00125% epinephrine
Number of subjects: 44
Study 7063178 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cm3 of Xylocitin 2% with 0.002% epinephrine
Number of subjects: 44
Study 7063178 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cm3 of Xylocitin 2% with 0.005% norepinephrine
Number of subjects: 44
Study 7063178 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cm3 of Xylocitin 2% alone
Number of subjects: 44
Study 7063178 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo) or needle insertion only
Number of subjects: 44
Study 31983019 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Approach to Weight Management and Food in Eating Disorders (HAPIFED)
Number of subjects: 98
Study 31983019 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy-Enhanced (CBT-E)
Number of subjects: 98
Study 29630438 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 malaria vaccine co-administered with PHiD-CV and HRV
Number of subjects: 705
Study 29630438 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 co-administered with PHiD-CV
Number of subjects: 705
Study 29630438 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 co-administered with HRV
Number of subjects: 705
Study 29630438 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 co-administered with aP antigens
Number of subjects: 705
Study 29630438 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV co-administered with RTS,S/AS01
Number of subjects: 705
Study 29630438 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01
Number of subjects: 705
Study 29630438 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 co-administered with pediatric vaccines
Number of subjects: 705
Study 29630438 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 and co-administered PHiD-CV, pertussis antigens and HRV
Number of subjects: 705
Study 29630438 — intervention group
Group type: COMPARATOR
Intervention: HBV (Engerix B) vaccine
Number of subjects: 705
Study 27105760 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 1462
Study 27105760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1462
Study 25502179 — intervention group
Group type: EXPERIMENTAL
Intervention: CERA administered every two weeks (Q2W)
Number of subjects: 50
Study 25502179 — intervention group
Group type: COMPARATOR
Intervention: CERA administered every four weeks (Q4W)
Number of subjects: 50
Study 23301484 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture treatment at Baihui (GV 20), pain point (Extra, right), Sanyangluo (TE 8, right), Zusanli (ST 36, right), and ear uterus point (right ear) after 50 mg dolantin injection
Number of subjects: 134
Study 23301484 — intervention group
Group type: COMPARATOR
Intervention: Control group received 50 mg dolantin injection followed by oocyte retrieval after 30 min
Number of subjects: 134
Study 20350923 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D treatment (group D)
Number of subjects: 28
Study 20350923 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 28
Study 18609301 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain patients
Number of subjects: 15
Study 18609301 — intervention group
Group type: COMPARATOR
Intervention: Controls (non-obese adults)
Number of subjects: 15
Study 16321131 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly designed thumb strap splint and abduction exercise regimen
Number of subjects: 40
Study 16321131 — intervention group
Group type: COMPARATOR
Intervention: Current clinical practice (short opponens splint and pinch exercise regimen)
Number of subjects: 40
Study 14610125 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution MRI in patients with ICD
Number of subjects: 10
Study 14610125 — intervention group
Group type: COMPARATOR
Intervention: High-resolution MRI in healthy controls
Number of subjects: 10
Study 11190415 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole for antifungal prophylaxis in patients with prolonged neutropenia
Number of subjects: 0
Study 11190415 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amphotericin B at a daily dose of 0.6 to 1 mg/kg
Number of subjects: 0
Study 11190415 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid formulations of amphotericin B
Number of subjects: 0
Study 11190415 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B for unstable candidiasis
Number of subjects: 0
Study 11190415 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole as an alternative
Number of subjects: 0
Study 11190415 — intervention group
Group type: EXPERIMENTAL
Intervention: New antifungal agents (new azoles)
Number of subjects: 0
Study 8887592 — intervention group
Group type: EXPERIMENTAL
Intervention: Index hospital stay
Number of subjects: 1016
Study 8887592 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality rates
Number of subjects: 1016
Study 8887592 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of index hospital stay
Number of subjects: 1016
Study 8887592 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of index hospital stay
Number of subjects: 1016
Study 8887592 — intervention group
Group type: EXPERIMENTAL
Intervention: Readmission rates
Number of subjects: 1016
Study 8887592 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life at 6 months
Number of subjects: 1016
Study 8887592 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival time
Number of subjects: 1016
Study 1291567 — intervention group
Group type: EXPERIMENTAL
Intervention: Subzonal insemination (SUZI); 11 cycles in the first part of the study.
Number of subjects: 27
Study 1291567 — intervention group
Group type: EXPERIMENTAL
Intervention: Subzonal insemination (SUZI); 35 cycles in the second part of the study.
Number of subjects: 27
Study 1291567 — intervention group
Group type: COMPARATOR
Intervention: Classic IVF insemination; 11 cycles in the first part of the study.
Number of subjects: 27
Study 3881006 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 36
Study 3881006 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 20 mg
Number of subjects: 36
Study 3881006 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nifedipine and isosorbide dinitrate
Number of subjects: 36
Study 3881006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31637821 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention: Six-monthly repeat home-based HIV counselling and testing (RHBCT) and referral of PLHIV to local HIV clinics, ART initiated regardless of CD4 count.
Number of subjects: 8563
Study 31637821 — intervention group
Group type: COMPARATOR
Intervention: Control: ART initiated according to national guidelines.
Number of subjects: 8563
Study 30499484 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic treatment combined with pharmacotherapy
Number of subjects: 106
Study 30499484 — intervention group
Group type: COMPARATOR
Intervention: Medicamentous treatment alone (Control)
Number of subjects: 106
Study 30499484 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy and massage (Comparison group)
Number of subjects: 106
Study 26808991 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI with stenting and distal protection device (for both genders)
Number of subjects: 501